MENINGOCOCCAL VACCINES IN INFANT RHESUS MACAQUES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 儿童脑膜炎奈瑟菌感染仍然是严重神经系统后遗症的重要原因，常规疫苗接种无效。中和抗体和杀菌抗体都是保护性的，但婴儿的免疫系统对荚膜多糖免疫原没有足够的反应。该项目测试了几种用不同佐剂配制的脑膜炎双球菌免疫原，旨在提高婴儿宿主的杀菌抗体反应。经筛选无脑膜炎抗体的恒河猴婴儿饲养在野外自然环境中，将在3个月大时接种脑膜炎双球菌疫苗，然后在4个月大时进行加强注射。本次免疫原性研究将测定杀菌抗体效价。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pediatric infection with Neisseria meningititidis remains an important cause of serious illness with neurologic sequellae for which conventional vaccination has been ineffective. Both neutralizing and bactericidal antibodies are protective but the infant immune system does not respond adequately to capsular polysaccharide immunogens. This project tests several meningococcal immunogens formulated with different adjuvants designed to improve the bactericidal antibody response in the infant host. Infant rhesus monkeys, screened for absence of meningoccal antibody and housed in a natural environment, the outdoor field cage, will be immunized with meningococcal vaccines at 3 months of age, followed by a booster injection at 4 months. The titers of bactericidal antibody will be measured in this immunogenicity study.